Recent

% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

bababara00 5 posts  |  Last Activity: Jun 5, 2015 9:21 AM Member since: May 21, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Symphony for 5/29

    by bronze00550 Jun 5, 2015 9:08 AM
    bababara00 bababara00 Jun 5, 2015 9:21 AM Flag

    ADD KOREA

  • bababara00 bababara00 May 12, 2015 5:59 PM Flag

    while they battle for 2 years to see who pays for a 7 year study

    I'll watch Arna go to 50

  • Reply to

    Bought 5.15 in AH Session

    by glenntrader May 12, 2015 5:23 PM
    bababara00 bababara00 May 12, 2015 5:24 PM Flag

    I shorted more at 6.45

  • Reply to

    Is this prioritization really bad?

    by shamcy May 7, 2015 5:04 PM
    bababara00 bababara00 May 9, 2015 8:53 AM Flag

    La Jolla (LJPC)
    Discontinuation of Ph2 GCS-100 Softened by
    New Preclinical Assets Acquisition

    Key Takeaway
    On uncertain development path from FDA feedback, LJPC discontinues GCS-100
    program for CKD, which we've viewed as a high-risk product. This is partly
    offset by the acquisition of two preclinical candidates LJPC-30Sa & -30Sb (nextgen
    gentamicin derivatives) for antimicrobial & rare genetics diseases (timing
    for IND filing uncertain at present). For lead product LJPC-501 in CRH, Ph3 data
    is on track for ~fall-2016.
    From recent FDA feedback & expert discussions, LJPC has decided to discontinue
    GCS-100 & LJPC-1010 programs for CKD. FDA indicated in recent discussions that
    LJPC would be required to conduct additional chemical characterization of GCS-100 prior
    to further clinical development (techniques enabling cross-trial comparison); feasibility/
    timeframe of such is highly difficult/unknown based on its expert consultations. Thus,
    LJPC is now seeking to out-license these product candidates. We previously estimated 30%
    probability of success for GCS-100 in CKD given high clinical hurdles.
    LJPC now adds two preclinical candidates LJPC-30Sa & -30Sb (next-generation
    gentamicin derivatives) for antimicrobial & rare genetics diseases (e.g., CF,
    DMD); timing for IND filing undisclosed. LJPC has entered into an exclusive agreement
    to acquire the Indiana University Research and Technology Center's (IURTC) IP rights for
    next-generation gentamicin derivatives. Two lead development candidates are LJPC-30Sa for
    antimicrobial indications and LJPC-30Sb for rare genetic diseases (e.g. cystic fibrosis [CF] and
    Duchenne Muscular Dystrophy [DMD]). LJPC notes low hurdles to advance these candidates
    to clinic given specific guidance from the FDA (i.e., manufacture of final drug product, but
    animal toxicology studies not required).
    Resetting PT to $22/sh (from $25/sh) primarily on removal of GCS-100 for CKD
    and roughly $100M asset value addition for gentamicin derivatives program
    (albeit subjective). Our new $22 PT now includes LJPC-30Sa/LJPC-30Sb asset value of $100M
    (~$5/sh). Previously we had ~$8/sh for GCS-100 in CKD.
    Valuation/Risks
    Our $22 PT is based on ~$17/sh for LJPC-501 in CRH and ~$5/sh for early-stage asset value
    (e.g., gentamicin derivative program for antimicrobial/rare genetic diseases). Risks include
    clinical delay/failure for LJPC-501 in CRH and general industry risks.

    Resetting PT to $22/sh (from $25/sh) primarily on removal of GCS-100 in
    chronic kidney disease (CKD) from valuation partially offset by $100M
    technology value addition for gentamicin derivatives program. Given
    yesterday’s announcement of GCS-100 program discontinuation, we have removed our
    previous GCS-100 revenue estimates from our sum-of-the-parts analysis (~30%
    probability adjusted for both U.S/EU; $8/sh contribution on peak U.S. sales of ~$600M
    and peak EU royalty revenues of ~$59M assuming ~20% royalty rate). This decrease in
    present value is partially offset by the new addition of $100M in technology value
    associated with LJPC-30Sa & -30Sb (next-gen gentamicin derivatives) programs for
    antimicrobial & rare genetic diseases (e.g., CF, DMD), respectively. Given the early-stage
    nature of the gentamicin derivatives programs (IND filing timeline uncertain at present),
    we view it is prudent to assign a conservative technology value (vs. discretely valuing for
    each) prior to clinical trial entry.
    Our new $22 PT is based on an NPV analysis of ~$17/sh for LJPC-501 in catecholamineresistant
    hypotension (85% probability-adjusted for both U.S./EU; peak U.S. sales of
    ~$250M and peak EU royalty revenues of ~$31M in 2030) and early-stage technology
    value of ~$5/sh (total technology value of $100M for preclinical gentamicin derivatives
    program), using an annual discount rate of 12%.

  • Reply to

    Is this prioritization really bad?

    by shamcy May 7, 2015 5:04 PM
    bababara00 bababara00 May 8, 2015 3:39 PM Flag

    tutes took it from 14.14 to 19 in a few minutes

ZLCS
0.00(0.00%)